

Noemi Lois

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8457565/publications.pdf>

Version: 2024-02-01

72
papers

3,450
citations

279487

23
h-index

155451

55
g-index

74
all docs

74
docs citations

74
times ranked

3832
citing authors

#	ARTICLE	IF	CITATIONS
1	Vitreotomy, subretinal Tissue plasminogen activator and Intravitreal Gas for submacular haemorrhage secondary to Exudative Age-Related macular degeneration (TIGER): study protocol for a phase 3, pan-European, two-group, non-commercial, active-control, observer-masked, superiority, randomised controlled surgical trial. <i>Trials</i> , 2022, 23, 99.	0.7	8
2	Predictive factors associated with anatomical and functional outcomes following panretinal photocoagulation in people with proliferative diabetic retinopathy. <i>Retina</i> , 2022, Publish Ahead of Print, .	1.0	0
3	Patients views on a new surveillance pathway involving allied non-medical staff for people with treated diabetic macular oedema and proliferative diabetic retinopathy. <i>Eye</i> , 2022, , .	1.1	1
4	Evaluation of a New Model of Care for People with Complications of Diabetic Retinopathy. <i>Ophthalmology</i> , 2021, 128, 561-573.	2.5	15
5	Testing the performance of risk prediction models to determine progression to referable diabetic retinopathy in an Irish type 2 diabetes cohort. <i>British Journal of Ophthalmology</i> , 2021, , bjophthalmol-2020-318570.	2.1	3
6	Multimodal imaging interpreted by graders to detect re-activation of diabetic eye disease in previously treated patients: the EMERALD diagnostic accuracy study. <i>Health Technology Assessment</i> , 2021, 25, 1-104.	1.3	1
7	Anatomicâ€“Functional Correlates in Lesions of Retinal Vein Occlusion. , 2021, 62, 10.		3
8	Surveillance of people with previously successfully treated diabetic macular oedema and proliferative diabetic retinopathy by trained ophthalmic graders: cost analysis from the EMERALD study. <i>British Journal of Ophthalmology</i> , 2021, , bjophthalmol-2021-318816.	2.1	1
9	Reporting of Complications in Retinal Detachment Surgical Trials. <i>JAMA Ophthalmology</i> , 2021, 139, 898.	1.4	3
10	Reply. <i>Ophthalmology</i> , 2021, 128, e46-e47.	2.5	0
11	The importance of the epithelial fibre cell interface to lens regeneration in an in vivo rat model and in a human bag-in-the-lens (BiL) sample. <i>Experimental Eye Research</i> , 2021, 213, 108808.	1.2	4
12	FIRST FAILED MACULAR HOLE SURGERY OR REOPENING OF A PREVIOUSLY CLOSED HOLE. <i>Retina</i> , 2020, 40, 1-15.	1.0	28
13	IMPACT OF RETINAL ISCHEMIA ON FUNCTIONAL AND ANATOMICAL OUTCOMES AFTER ANTIâ€“VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN PATIENTS WITH RETINAL VEIN OCCLUSION. <i>Retina</i> , 2020, 40, 1098-1109.	1.0	3
14	Reply. <i>Retina</i> , 2020, 40, e48-e49.	1.0	0
15	Prognostic factors for the development and progression of proliferative diabetic retinopathy in people with diabetic retinopathy. <i>The Cochrane Library</i> , 2020, , .	1.5	1
16	A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema. <i>Journal of Clinical Medicine</i> , 2020, 9, 2225.	1.0	7
17	Targeting QKI-7 in vivo restores endothelial cell function in diabetes. <i>Nature Communications</i> , 2020, 11, 3812.	5.8	39
18	Endothelial Cells Derived From Patients With Diabetic Macular Edema Recapitulate Clinical Evaluations of Anti-VEGF Responsiveness Through the Neuronal Pentraxin 2 Pathway. <i>Diabetes</i> , 2020, 69, 2170-2185.	0.3	9

#	ARTICLE	IF	CITATIONS
19	Risk factors associated with progression to referable retinopathy: a type 2 diabetes mellitus cohort study in the Republic of Ireland. <i>Diabetic Medicine</i> , 2020, 37, 1000-1007.	1.2	7
20	PRAGMATISM OF RANDOMIZED CLINICAL TRIALS ON RANIBIZUMAB FOR THE TREATMENT OF DIABETIC MACULAR EDEMA. <i>Retina</i> , 2020, 40, 919-927.	1.0	5
21	Circulating Leukocyte Alterations and the Development/Progression of Diabetic Retinopathy in Type 1 Diabetic Patients - A Pilot Study. <i>Current Eye Research</i> , 2020, 45, 1144-1154.	0.7	19
22	Visual cycle modulators versus placebo or observation for the prevention and treatment of geographic atrophy due to age-related macular degeneration. <i>The Cochrane Library</i> , 2020, 12, CD013154.	1.5	7
23	Effectiveness of Multimodal imaging for the Evaluation of Retinal oedema And new vessels in Diabetic retinopathy (EMERALD). <i>BMJ Open</i> , 2019, 9, e027795.	0.8	7
24	STAT3 activation in circulating myeloid-derived cells contributes to retinal microvascular dysfunction in diabetes. <i>Journal of Neuroinflammation</i> , 2019, 16, 138.	3.1	22
25	Reply to Correspondence by Calugaru and Calugaru to the Article Entitled "Ischemic retinal vein occlusion: characterizing the more severe spectrum of retinal vein occlusion" by Khayat et al.. <i>Survey of Ophthalmology</i> , 2019, 64, 593-594.	1.7	0
26	Diabetic macular oedema and diode subthreshold micropulse laser (DIAMONDS): study protocol for a randomised controlled trial. <i>Trials</i> , 2019, 20, 122.	0.7	22
27	Fenofibrate for Diabetic Retinopathy. <i>Asia-Pacific Journal of Ophthalmology</i> , 2019, 7, 422-426.	1.3	14
28	Enhanced Function of Induced Pluripotent Stem Cell-Derived Endothelial Cells Through ESM1 Signaling. <i>Stem Cells</i> , 2019, 37, 226-239.	1.4	25
29	Ischemic retinal vein occlusion: characterizing the more severe spectrum of retinal vein occlusion. <i>Survey of Ophthalmology</i> , 2018, 63, 816-850.	1.7	73
30	Different lasers and techniques for proliferative diabetic retinopathy. <i>The Cochrane Library</i> , 2018, 2018, CD012314.	1.5	32
31	Instrumental variable methods for a binary outcome were used to informatively address noncompliance in a randomized trial in surgery. <i>Journal of Clinical Epidemiology</i> , 2018, 96, 126-132.	2.4	6
32	Treatment for diabetic macular oedema: looking further into the evidence. <i>Annals of Eye Science</i> , 2018, 3, 2-2.	1.1	1
33	Visual cycle modulators versus placebo or observation for the prevention and treatment of geographic atrophy due to age-related macular degeneration. <i>The Cochrane Library</i> , 2018, , .	1.5	1
34	Polarized retinal pigment epithelium generates electrical signals that diminish with age and regulate retinal pathology. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 5552-5564.	1.6	9
35	Vitreomacular interface abnormalities in patients with diabetic macular oedema and their implications on the response to anti-VEGF therapy. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2018, 256, 1411-1418.	1.0	11
36	Treatments for dry age-related macular degeneration and Stargardt disease: a systematic review. <i>Health Technology Assessment</i> , 2018, 22, 1-168.	1.3	43

#	ARTICLE	IF	CITATIONS
37	Diabetic retinopathy and the use of laser photocoagulation: is it cost-effective to treat early?. <i>BMJ Open Ophthalmology</i> , 2017, 2, e000021.	0.8	10
38	The Epidemiology of Stargardt Disease in the United Kingdom. <i>Ophthalmology Retina</i> , 2017, 1, 508-513.	1.2	19
39	Erythropoietin in diabetic retinopathy. <i>Vision Research</i> , 2017, 139, 237-242.	0.7	18
40	Animal Models of Retinal Vein Occlusion. , 2017, 58, 6175.		28
41	The progress in understanding and treatment of diabetic retinopathy. <i>Progress in Retinal and Eye Research</i> , 2016, 51, 156-186.	7.3	730
42	Optical Coherence Tomography for the Monitoring of Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2015, 122, 399-406.	2.5	55
43	Pan-retinal photocoagulation and other forms of laser treatment and drug therapies for non-proliferative diabetic retinopathy: systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2015, 19, 1-248.	1.3	53
44	Treatments for macular oedema following central retinal vein occlusion: systematic review. <i>BMJ Open</i> , 2014, 4, e004120.	0.8	21
45	Endothelial Progenitor Cells in Diabetic Retinopathy. <i>Frontiers in Endocrinology</i> , 2014, 5, 44.	1.5	67
46	Drug treatment of macular oedema secondary to central retinal vein occlusion: a network meta-analysis. <i>BMJ Open</i> , 2014, 4, e005292-e005292.	0.8	26
47	Vitrectomy with Internal Limiting Membrane Peeling versus No Peeling for Idiopathic Full-Thickness Macular Hole. <i>Ophthalmology</i> , 2014, 121, 649-655.	2.5	149
48	Fundus autofluorescence in patients with retinal pigment epithelial (RPE) tears: an in-vivo evaluation of RPE resurfacing. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2014, 252, 1059-1063.	1.0	19
49	Optical coherence tomography for the diagnosis, monitoring and guiding of treatment for neovascular age-related macular degeneration: a systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2014, 18, 1-254.	1.3	17
50	A Longitudinal Study of Stargardt Disease: Clinical and Electrophysiologic Assessment, Progression, and Genotype Correlations. <i>American Journal of Ophthalmology</i> , 2013, 155, 1075-1088.e13.	1.7	121
51	RETINAL PIGMENT EPITHELIAL ATROPHY IN PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION UNDERGOING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. <i>Retina</i> , 2013, 33, 13-22.	1.0	76
52	Reply. <i>Retina</i> , 2013, 33, 1998-1999.	1.0	0
53	Cost-effectiveness of internal limiting membrane peeling versus no peeling for patients with an idiopathic full-thickness macular hole: results from a randomised controlled trial. <i>British Journal of Ophthalmology</i> , 2012, 96, 438-443.	2.1	24
54	Progression of Retinal Pigment Epithelial Atrophy in Stargardt Disease. <i>American Journal of Ophthalmology</i> , 2012, 154, 146-154.	1.7	82

#	ARTICLE	IF	CITATIONS
55	GEOGRAPHIC ATROPHY IN RETINAL ANGIOMATOUS PROLIFERATION. <i>Retina</i> , 2011, 31, 1043-1052.	1.0	73
56	Internal Limiting Membrane Peeling versus No Peeling for Idiopathic Full-Thickness Macular Hole: A Pragmatic Randomized Controlled Trial. , 2011, 52, 1586.		220
57	Progression of Electroretinogram Responses in Stargardtâ€™Fundus Flavimaculatus: A longitudinal study. <i>Acta Ophthalmologica</i> , 2011, 89, 0-0.	0.6	1
58	Electric currents and lens regeneration in the rat. <i>Experimental Eye Research</i> , 2010, 90, 316-323.	1.2	21
59	Electrical stimulation of retinal pigment epithelial cells. <i>Experimental Eye Research</i> , 2010, 91, 195-204.	1.2	20
60	Clinical and cost-effectiveness of internal limiting membrane peeling for patients with idiopathic full thickness macular hole. Protocol for a Randomised Controlled Trial: FILMS (Full-thickness macular) Tj ETQq0 0 0 rgBT.7Overload 10 Tf 50		
61	Internal Limiting Membrane Peeling in Vitreo-retinal Surgery. <i>Survey of Ophthalmology</i> , 2008, 53, 368-396.	1.7	94
62	Environmental tobacco smoke exposure and eye disease. <i>British Journal of Ophthalmology</i> , 2008, 92, 1304-1310.	2.1	85
63	Effect of short-term macrophage depletion in the development of posterior capsule opacification in rodents. <i>British Journal of Ophthalmology</i> , 2008, 92, 1528-1533.	2.1	9
64	Posterior Capsule Opacification in Mice. <i>JAMA Ophthalmology</i> , 2005, 123, 71.	2.6	28
65	Effect of TGF-Î²2 and Antiâ€™TGF-Î²2 Antibody in a New In Vivo Rodent Model of Posterior Capsule Opacification. , 2005, 46, 4260.		24
66	Fundus autofluorescence in stargardt macular dystrophyâ€™fundus flavimaculatus. <i>American Journal of Ophthalmology</i> , 2004, 138, 55-63.	1.7	167
67	Pseudophakic retinal detachment. <i>Survey of Ophthalmology</i> , 2003, 48, 467-487.	1.7	173
68	A New Model of Posterior Capsule Opacification in Rodents. , 2003, 44, 3450.		51
69	Fundus autofluorescence in patients with age-related macular degeneration and high risk of visual loss11Commercial interests: None.. <i>American Journal of Ophthalmology</i> , 2002, 133, 341-349.	1.7	179
70	Phenotypic Subtypes of Stargardt Macular Dystrophyâ€™Fundus Flavimaculatus. <i>JAMA Ophthalmology</i> , 2001, 119, 359.	2.6	278
71	Intrafamilial variation of phenotype in Stargardt macular dystrophy-Fundus flavimaculatus. <i>Investigative Ophthalmology and Visual Science</i> , 1999, 40, 2668-75.	3.3	58
72	Fenofibrate for diabetic retinopathy. <i>The Cochrane Library</i> , 0, , .	1.5	4